Roche took another step closer to raising all the cash needed for the Swiss pharmaceuticals company’s proposed $42bn takeover of US biotech group Genentech when it sold more than €11bn worth of bonds on Wednesday.

The Swiss company has now raised more than $30bn in the past week between Wednesday’s European deal and its earlier multi-tranche $16bn US dollar bond sale, with both deals breaking records.